As with all licensed medicines, we will continue to monitor its safety closely as it becomes more widely used
Similar Posts
NHS red tape blitz delivers game-changing new cancer treatment
Patients to benefit from new era in cancer treatment, as Government slashes red tape to unleash life-saving innovation
Patients will receive medicines 3-6 months faster under 10-Year Health Plan, as regulators set out plans
Under a joint information sharing agreement, pharmaceutical companies will be invited to register early with the MHRA and NICE to allow parallel decision making over licencing and value.
AI Airlock, CERSIs and a new global AI network for health regulators
Med Tech Regs blog, June 2025: A focus on Software and AI.
Notice: Medicines: terminated and cancelled manufacturing and wholesale dealer licences
UK companies who have their licence to manufacture or wholesale medicines terminated and cancelled.
Class 4 Medicines Defect Notification: Topiramate Zydus Pharmaceuticals UK 20mg/ml Oral Solution, Zydus Pharmaceuticals UK Ltd, EL(25)A/39
Zydus Pharmaceuticals UK LTD has informed the MHRA that there is an error on the artwork for the outer carton and Patient Information Leaflet (PIL) of Topiramate Zydus Pharmaceuticals UK 20mg/ml Oral Solution (pack size 150ml and 280ml bottles).
Research: Improving information supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs
Public Assessment Report on improving information regarding addiction, dependence, withdrawal, and tolerance for gabapentin, pregabalin, benzodiazepines, and z-drugs.